Phase I study to investigate the safety and efficacy of TUR-002 for the treatment of Major Depressive Disorder (MDD).
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Jan 2016
At a glance
- Drugs Ketamine (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions; Therapeutic Use
- 14 Jan 2016 Status changed from planning to not yet recruiting, as reported in a Turing Pharmaceuticals media release.
- 08 Jan 2016 New trial record
- 12 Nov 2015 According to the media release of Turing Pharmaceuticals, this trial is planned to initiate by first quarter of 2016.